Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
•
SABCS 2025
How will LORETTA and COMET trials influence treatment of low-risk DCIS?
Related Questions
What potential challenges do you foresee in transitioning from current endocrine therapies to giredestrant, based on the lidERA trial results, in ER+, HER2- early breast cancer?
What are your top takeaways in Medical Oncology from SABCS 2025?
Will the results of Alliance A011104/ACRIN 6694 change your current practice regarding preoperative MRI’s in patients with newly-diagnosed, early stage breast cancer?
What are your top takeaways in Radiation Oncology from SABCS 2025?
How do the ALTTO trial findings influence your choice of adjuvant endocrine therapy (AI with or without ovarian function suppression versus SERM-based therapy) for patients with HR+/HER2+ early breast cancer?
Considering the results of the I-SPY2 trial discussed at ASCO 2025, what would be your approach to treating a T1cN0 (tumor 1.5-1.9cm) young, fit patient? NACT THP x4 or surgery upfront?
Would you consider adjuvant capecitabine for a patient with triple-negative metaplastic carcinoma who has microinvasive residual disease (ypT1miN0) following neoadjuvant therapy?
How would you treat a T2N1 ER 90%, PR 10%, HER-2 negative breast cancer in premenopausal women with a tumor abutting the pectoralis fascia with loss of fat plane, with a concern for a positive surgical margin?
Would you offer adjuvant ribociclib to a postmenopausal female with ER+ luminal A, node+ breast cancer pT1cN1a grade 2 that didn't require chemotherapy per OncoType, but met NATALEE inclusion criteria?
Do you make dose modifications to KEYNOTE-522 regimen in the elderly?
